[HTML][HTML] Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
…, F Lang, R Hansen, S Isfort, K Schmitt, E Jost… - Journal of hematology & …, 2016 - Springer
Background Patients with Ph-negative myeloproliferative neoplasms (MPN), such as
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at …
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at …
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer …
…, M Crysandt, A Esser, R Osieka, E Jost - Journal of cancer …, 2009 - Springer
Purpose The renin-angiotensin system plays a crucial role in maintaining vascular
homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by …
homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by …
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
…, V Kunzmann, H Einsele, E Jost… - Blood, The Journal …, 2020 - ashpublications.org
In fit patients with newly diagnosed acute myeloid leukemia (AML), immediate treatment start
is recommended due to the poor prognosis of untreated acute leukemia. We explored the …
is recommended due to the poor prognosis of untreated acute leukemia. We explored the …
[HTML][HTML] Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo …
…, A Elmaagacli, KS Götze, C Schmid, E Jost… - Blood, 2018 - Elsevier
Introduction: Most patients with FLT3-ITD-positive AML, who relapse after allogenic stem cell
transplantation (allo-SCT) die from their disease. Whether prophylactic FLT3-ITD inhibition …
transplantation (allo-SCT) die from their disease. Whether prophylactic FLT3-ITD inhibition …
[HTML][HTML] Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
…, M Höfs, P Hundsdoerfer, E Jost… - The Journal of …, 2023 - Am Soc Clin Investig
BACKGROUND Adoptive transfer of EBV-specific T cells can restore specific immunity in
immunocompromised patients with EBV-associated complications. METHODS We provide …
immunocompromised patients with EBV-associated complications. METHODS We provide …
[HTML][HTML] Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation
R Ummanni, E Jost, M Braig, F Lohmann, F Mundt… - Molecular cancer, 2011 - Springer
Background We have previously reported significant downregulation of ubiquitin carboxyl-terminal
hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign …
hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign …
[HTML][HTML] Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer
J Veeck, E Noetzel, N Bektas, E Jost, A Hartmann… - Molecular Cancer, 2008 - Springer
Background We have previously reported that expression of the Wnt antagonist genes SFRP1
and SFRP5 is frequently silenced by promoter hypermethylation in breast cancer. SFRP2 …
and SFRP5 is frequently silenced by promoter hypermethylation in breast cancer. SFRP2 …
Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2× 2, phase II …
…, O Grishina, C Schmoor, RF Schlenk, E Jost… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE DNA-hypomethylating agents are studied in combination with other epigenetic
drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in …
drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in …
In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia …
…, LP Mueller, S Christoph, SW Krause, W Bethge, E Jost… - Blood, 2022 - ashpublications.org
Introduction: For patients (pts) with AML, a complete remission (CR) prior to allogeneic
hematopoietic cell transplantation (alloHCT) is a favourable risk factor. However, whether pts with …
hematopoietic cell transplantation (alloHCT) is a favourable risk factor. However, whether pts with …
[HTML][HTML] Drugging the unfolded protein response in acute leukemias
B Kharabi Masouleh, E Chevet, J Panse, E Jost… - Journal of hematology & …, 2015 - Springer
The unfolded protein response (UPR), an endoplasmic reticulum (ER) stress-induced signaling
cascade, is mediated by three major stress sensors IRE-1α, PERK, and ATF6α. Studies …
cascade, is mediated by three major stress sensors IRE-1α, PERK, and ATF6α. Studies …